Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]
News [3223]
Articles [134]
Editorials [3]
Conferences [121]
elearning [18]
Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive...
Dr Ryotaro Nakamura - City of Hope, California, USA
Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive care in older patients with advanced MDS ( Dr Ryotaro Nakamura - City of Hope, California, USA )
17 Feb 2021
OncoAlert and ecancer weekly roundup for February 01 - 06, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for February 01 - 06, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
9 Feb 2021
Emerging treatments for relapsed/refractory Hodgkin’s lymphoma in China
Dr Qingqing Cai - Sun Yat-Sen University, Guangzhou, China
Emerging treatments for relapsed/refractory Hodgkin’s lymphoma in China ( Dr Qingqing Cai - Sun Yat-Sen University, Guangzhou, China )
29 Jan 2021
OncoAlert and ecancer weekly roundup for January 11 - 17, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for January 11 - 17, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
21 Jan 2021
Haematology updates from SIOG 2020
Dr Tanya Wildes - SIOG Science & Education Committee Chair
Haematology updates from SIOG 2020 ( Dr Tanya Wildes - SIOG Science & Education Committee Chair )
13 Jan 2021
The Burkitt lymphoma international prognostic index
Prof Adam Olszewski - Brown University, Providence, USA
The Burkitt lymphoma international prognostic index ( Prof Adam Olszewski - Brown University, Providence, USA )
24 Dec 2020
OncoAlert Colloquium Day 4: Gynae-oncology, lymphoma, sarcoma and melanoma
Dr Dizon, Dr Trent, Dr Cordoba, Dr Rolfo, Dr Haanen
OncoAlert Colloquium Day 4: Gynae-oncology, lymphoma, sarcoma and melanoma ( Dr Dizon, Dr Trent, Dr Cordoba, Dr Rolfo, Dr Haanen )
23 Dec 2020
Results of venetoclax and azacitidine combination in chemotherapy ineligible...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with AML ( Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA )
22 Dec 2020
Long-term follow-up of low-intensity chemotherapy with combination therapy for...
Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA
Long-term follow-up of low-intensity chemotherapy with combination therapy for r/r Ph- acute lymphoblastic leukaemia patients ( Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA )
22 Dec 2020
Real-world evidence of the use of carfilzomib among multiple myeloma patients...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib among multiple myeloma patients across 10 European countries and Israel ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
Real-world evidence of the use of carfilzomib to refractory to lenalidomide...
Prof Evangelos Terpos - University of Athens, Athens, Greece
Real-world evidence of the use of carfilzomib to refractory to lenalidomide patients ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020
A treatment comparison of carfilzomib, dexamethasone and daratumumab to...
Prof Evangelos Terpos - University of Athens, Athens, Greece
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumumab and bortezomib ( Prof Evangelos Terpos - University of Athens, Athens, Greece )
22 Dec 2020

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation